The combination of fatty liver and increased gamma-glutamyl transpeptidase levels as a risk factor for atherosclerotic plaque development in apparently healthy people
Multivariate analysis revealed that the combination of fatty liver and a serum GGT level ≥50 U/L was the only significantrisk factor for carotid plaque occurrence (age- and sex-adjusted hazard ratio: 5.55; 95% confidence interval 1.70–18.14; P = 0.005).Conclusion: The combination of fatty liver and increased serum GGT levels raises the risk for atherosclerotic plaque development inapparently healthy people.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/aim: To elucidate how the combination of fatty liver and increased serum gamma-glutamyl transpeptidase (GGT) levelsinfluences atherosclerotic plaque development in apparently healthy people.Materials and methods: The study population included people who had received an annual health checkup for more than 7 years andhad no evidence of carotid plaque at baseline.
📊
Key Findings & Data:We investigated the risk factors for carotid plaque occurrence using the Cox proportionalhazards model.Results: A total of 107 people (76 men and 31 women; median age, 49 years) were enrolled.
💡
Conclusion & Impact:Multivariate analysis revealed that the combination of fatty liver and a serum GGT level ≥50 U/L was the only significantrisk factor for carotid plaque occurrence (age- and sex-adjusted hazard ratio: 5.55; 95% confidence interval 1.70–18.14; P = 0.005).Conclusion: The combination of fatty liver and increased serum GGT levels raises the risk for atherosclerotic plaque development inapparently healthy people.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Background/aim: To elucidate how the combination of fatty liver and increased serum gamma-glutamyl transpeptidase (GGT) levelsinfluences atherosclerotic plaque development in apparently healthy people.Materials and methods: The study population included people who had received an annual health checkup for more than 7 years andhad no evidence of carotid plaque at baseline. We investigated the risk factors for carotid plaque occurrence using the Cox proportionalhazards model.Results: A total of 107 people (76 men and 31 women; median age, 49 years) were enrolled. At baseline, fatty liver and a serum GGTlevel ≥50 U/L were observed in 13 and 38 people, respectively. During a median follow-up period of 13.3 years, carotid plaques appearedin 34 people. Multivariate analysis revealed that the combination of fatty liver and a serum GGT level ≥50 U/L was the only significantrisk factor for carotid plaque occurrence (age- and sex-adjusted hazard ratio: 5.55; 95% confidence interval 1.70–18.14; P = 0.005).Conclusion: The combination of fatty liver and increased serum GGT levels raises the risk for atherosclerotic plaque development inapparently healthy people.
🔖
Cite This Article
UEDA, Y., TOSHIKUNI, N., MINATO, T., MATSUE, Y., KINOSHITA, K., SAITO, T., TSUCHISHIMA, M., HAYASHI, N., TSUTSUMI, M. (2022). The combination of fatty liver and increased gamma-glutamyl transpeptidase levels as a risk factor for atherosclerotic plaque development in apparently healthy people. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 5, 1350–1357. https://ajindex.com/articles/610147
Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. American Journal of Medicine 2009
122 (1 Suppl): S3-s14. doi: 10.1016/j. amjmed.2008.10.013 2. Pucci A, Franzini M, Matteucci M, Ceragioli S, Marconi M et al. b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. Atherosclerosis 2014
237 (1): 307-313. doi: 10.1016/j.atherosclerosis.2014.09.028 3. Belcastro E, Franzini M, Cianchetti S, Lorenzini E, Masotti S et al. Monocytes/macrophages activation contributes to b-gamma-glutamyltransferase accumulation inside atherosclerotic plaques. Journal of Translational Medicine 2015
doi: 10.1186/s12967-015-0687-6 4. Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clinica Chimica Acta 2018
doi: 10.1016/j. cca.2017.11.026 5. Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. Journal of Atherosclerosis and Thrombosis 2011
18 (3): 177-181. 6. Yang W, Kim CK, Kim DY, Jeong HG, Lee SH. Gamma-glutamyl transferase predicts future stroke: a Korean nationwide study. Annals of Neurology 2018
83 (2): 375-386. doi: 10.1002/ ana.25158 7. Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis. European Journal of Gastroenterology & Hepatology 2015
27 (11): 1237-1248. doi: 10.1097/meg.0000000000000429 8. Sinn DH, Cho SJ, Gu S, Seong D, Kang D et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology 2016
151 (3): 481-488.e481. doi: 10.1053/j.gastro.2016.06.001 9. Sinn DH, Kang D, Chang Y, Ryu S, Gu S et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017
66 (2): 323-329. doi: 10.1136/gutjnl-2016-311854 10. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008
16 (6): 1394-1399. doi: 10.1038/oby.2008.64 11. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine 2010
363 (14): 1341-1350. doi: 10.1056/ NEJMra0912063 12. Toshikuni N, Asaji T, Nakanishi Y, Nagasawa S-y, Uenishi H et al. Elevated serum gamma-glutamyl transpepti